Clinical Trials
Theravance Biopharma Announces First Patient Dosed in Phase 2b/3 Study of TD-1473 in Patients with Ulcerative Colitis
Theravance Biopharma, Inc.
PR-M03-19-NI-035Mar 13, 2019
Final Results
Final Results from the Protagonist PROPEL Study Support Further Clinical Development of PTG-100 for the Treatment of Ulcerative Colitis
Protagonist Therapeutics
PR-M08-18-NI-055Aug 14, 2018
FDA Approval
Pfizer Announces U.S. FDA Approves XELJANZ® (tofacitinib) for the Treatment of Moderately to Severely Active Ulcerative Colitis
Pfizer
PR-M06-18-NI-012Jun 05, 2018